Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab (JS001) PK and Safety in Advanced NSCLC Before and After Process Change
NCT03301688Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of toripalimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Area Under the Curve at 6 months. Started Sep 2017; status: completed.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03301688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301688.